Integrating Cell‐Based and Clinical Genome‐Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients. Issue 6 (18th February 2014)
- Record Type:
- Journal Article
- Title:
- Integrating Cell‐Based and Clinical Genome‐Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients. Issue 6 (18th February 2014)
- Main Title:
- Integrating Cell‐Based and Clinical Genome‐Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients
- Authors:
- Pinto, N
Gamazon, E R
Antao, N
Myers, J
Stark, A L
Konkashbaev, A
Im, H K
Diskin, S J
London, W B
Ludeman, S M
Maris, J M
Cox, N J
Cohn, S L
Dolan, M E - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>High‐risk neuroblastoma is an aggressive malignancy, with high rates of treatment failure. We evaluated genetic variants associated with <italic>in vitro</italic> sensitivity to two derivatives of cyclophosphamide for association with clinical response in a separate replication cohort of neuroblastoma patients (<italic>n</italic> = 2, 709). To determine sensitivity, lymphoblastoid cell lines (LCLs) were exposed to increasing concentrations of 4‐hydroperoxycyclophosphamide (4HC; <italic>n</italic> = 422) and phosphoramide mustard (PM; <italic>n</italic> = 428). Genome‐wide association studies were performed to identify single‐nucleotide polymorphisms (SNPs) associated with sensitivity to 4HC and PM. SNPs consistently associated with LCL sensitivity were analyzed for associations with event‐free survival (EFS) in patients. Two linked SNPs, rs9908694 and rs1453560, were found to be associated with (i) sensitivity to PM in LCLs across populations and (ii) EFS in all patients (<italic>P</italic> = 0.01) and within the high‐risk subset (<italic>P</italic> = 0.05). Our study highlights the value of cell‐based models to identify candidate variants that may predict response to treatment in patients with cancer.</p> <p> <italic>Clinical Pharmacology &amp; Therapeutics</italic> (2014); <bold>95</bold> 6, 644–652. doi:<ext-link ext-link-type="doi" xlink:type="simple"<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>High‐risk neuroblastoma is an aggressive malignancy, with high rates of treatment failure. We evaluated genetic variants associated with <italic>in vitro</italic> sensitivity to two derivatives of cyclophosphamide for association with clinical response in a separate replication cohort of neuroblastoma patients (<italic>n</italic> = 2, 709). To determine sensitivity, lymphoblastoid cell lines (LCLs) were exposed to increasing concentrations of 4‐hydroperoxycyclophosphamide (4HC; <italic>n</italic> = 422) and phosphoramide mustard (PM; <italic>n</italic> = 428). Genome‐wide association studies were performed to identify single‐nucleotide polymorphisms (SNPs) associated with sensitivity to 4HC and PM. SNPs consistently associated with LCL sensitivity were analyzed for associations with event‐free survival (EFS) in patients. Two linked SNPs, rs9908694 and rs1453560, were found to be associated with (i) sensitivity to PM in LCLs across populations and (ii) EFS in all patients (<italic>P</italic> = 0.01) and within the high‐risk subset (<italic>P</italic> = 0.05). Our study highlights the value of cell‐based models to identify candidate variants that may predict response to treatment in patients with cancer.</p> <p> <italic>Clinical Pharmacology &amp; Therapeutics</italic> (2014); <bold>95</bold> 6, 644–652. doi:<ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">10.1038/clpt.2014.37</ext-link></p> </abstract> … (more)
- Is Part Of:
- Clinical pharmacology & therapeutics. Volume 95:Issue 6(2014)
- Journal:
- Clinical pharmacology & therapeutics
- Issue:
- Volume 95:Issue 6(2014)
- Issue Display:
- Volume 95, Issue 6 (2014)
- Year:
- 2014
- Volume:
- 95
- Issue:
- 6
- Issue Sort Value:
- 2014-0095-0006-0000
- Page Start:
- 644
- Page End:
- 652
- Publication Date:
- 2014-02-18
- Subjects:
- Pharmacology -- Periodicals
Therapeutics -- Periodicals
615.5 - Journal URLs:
- http://www.nature.com/clpt/index.html ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1532-6535 ↗
http://www.nature.com/ ↗
http://firstsearch.oclc.org ↗
http://www.mosby.com/cpt ↗
http://www.sciencedirect.com/science/journal/00099236 ↗
http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action=searchDB&searchdbfor=home&id=cp ↗ - DOI:
- 10.1038/clpt.2014.37 ↗
- Languages:
- English
- ISSNs:
- 0009-9236
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.330000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3858.xml